Soligenix Reveals Q2 2025 Financial Report and Future Development Plans Soligenix, Inc. announces its second quarter 2025 financial results, affirming confidence in its late-stage biopharmaceutical projects addressing rare diseases.

Soligenix Reveals Q2 2025 Financial Report and Future Development Plans #USA #Princeton #Soligenix #HyBryte #SGX302

Soligenix Unveils Promising Advances in Rare Disease Treatments and Future Plans Soligenix's latest corporate update outlines significant progress in clinical trials for treating rare diseases like CTCL and psoriasis. Key milestones expected.

Soligenix Unveils Promising Advances in Rare Disease Treatments and Future Plans #USA #Princeton #Soligenix #HyBryte #SGX302